SCHEMBL3772178

SCHEMBL3772178

Cc1nc2ccc(NC(=O)O)cc2o1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.76
SMN1; SMN2 Q16637 3/20 0.72
ALDH1A1 P00352 4/20 0.67
HTR2C P28335 3/20 0.60
HTR2B P41595 2/20 0.60
RAB9A P51151 6/20 0.57
NPC1 O15118 4/20 0.57
STAT1 P42224 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.57
GAA P10253 3/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
MAPT P10636 4/20 0.56
HCRTR1 O43613 2/20 0.56
HCRTR2 O43614 2/20 0.56
ADORA2A P29274 2/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2D6 P10635 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246120 0.87 POLB (0.75) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL2244713 0.86 POLB (1.00) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL30128312 0.86 ALDH1A1 (0.71) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL16047712 0.84 SMN1; SMN2 (1.00) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL14911359 0.82 SMN1; SMN2 (0.64) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL30300541 0.81 POLB (0.62) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL31741395 0.80 POLB (0.58) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL5803669 0.80 HTR2C (0.75) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL14470503 0.80 POLB (0.68) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B
SCHEMBL13002974 0.80 ALDH1A1 (0.65) POLBSMN1; SMN2ALDH1A1HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 POLB 2770/4885SMN1; SMN2 2454/4885ALDH1A1 353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.